IN.TO - InMed Pharmaceuticals Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.4500
-0.0150 (-3.23%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.4650
Open0.4500
Bid0.4500 x 0
Ask0.4550 x 0
Day's Range0.4450 - 0.4600
52 Week Range0.3000 - 1.1400
Volume80,778
Avg. Volume186,285
Market Cap77.46M
Beta (3Y Monthly)6.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.10
  • CNW Group4 days ago

    InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

    InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

  • InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019
    PR Newswire11 days ago

    InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019

    TSX:IN OTCQX:IMLFF VANCOUVER, BC , May 8, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary ...

  • Have Insiders Been Buying InMed Pharmaceuticals Inc. (TSE:IN) Shares?
    Simply Wall St.23 days ago

    Have Insiders Been Buying InMed Pharmaceuticals Inc. (TSE:IN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we'll take...

  • InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
    CNW Group2 months ago

    InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology

    OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today announced the publication of the first in a series of pending patent applications directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.

  • InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
    PR Newswire2 months ago

    InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program

    OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a R&D pipeline of medications targeting diseases with high unmet medical needs, today provided an update on its drug development program for the treatment of Epidermolysis Bullosa ("EB").

  • CNW Group2 months ago

    InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019

    InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019

  • CNW Group2 months ago

    InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

    InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board

  • GlobeNewswire3 months ago

    Edison issues update on InMed Pharmaceuticals (IN)

    LONDON, Feb. 14, 2019 -- InMed (IN) recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis bullosa (EB) into the clinic by.

  • Market Exclusive3 months ago

    Cannabis Stock News Daily Roundup February 13

    Liht Cannabis (CSE: LIHT) (OTCQX: LIHTF) reported the preliminary results of its first harvest in Las Vegas, Nev. The company started harvesting the first of its six cultivation rooms earlier this month. Room One, comprised of popular strains such as Bubba Kush, Moonshine Ghost Train Haze, Amherst Sour Diesel, Skywalker and Lemon Skunk, has produced […]The post Cannabis Stock News Daily Roundup February 13 appeared first on Market Exclusive.

  • InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
    PR Newswire3 months ago

    InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

    TSX:IN OTCQX:IMLFF VANCOUVER , Feb. 12, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical ...

  • ACCESSWIRE3 months ago

    These Marijuana Stocks Should Be On Your Radar

    Although society has progressed much further in terms of recognizing the potential benefits of cannabis, there are still individuals who have yet to come to terms with the fact that more people are supportive of legalization. As a result of the recent passing of laws like the US Farm Bill, as well as Canada's country-wide legalization, individuals who would otherwise scoff at the cannabis industry, have now been brought into the fold due to the excitement surrounding the industry. Nabis Holdings (INNPF) (NAB), Amyris Inc (AMRS), InMed Pharmaceuticals Inc (IMLFF) (IN.TO), and Pyxus International Inc (PYX) are four cannabis companies working towards improving the quality of life for their consumers.

  • InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
    PR Newswire3 months ago

    InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019

    TSX:IN OTCQX:IMLFF VANCOUVER , Feb. 5, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical ...

  • InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer
    PR Newswire4 months ago

    InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Dr. Sazzad Hossain, PhD, MSc, will assume a position as member of the Scientific Advisory Board ("SAB") and, contemporaneously, announced his retirement as Chief Scientific Officer ("CSO").  Dr. Eric C. Hsu, PhD, Vice President, Pre-Clinical Research & Development, will continue to lead the scientific R&D programs of the Company.

  • InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019
    CNW Group4 months ago

    InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019

    VANCOUVER , Jan. 3, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (IN.TO) (IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will be presenting at the Biotech Showcase 2019 on Wednesday, January 9, 2019 , at 9:00 AM PT / 12:00 PM ET at the Hilton San Francisco Union Square, in San Francisco, California . A live audio webcast of the presentation will be available through InMed's corporate website in the 'Investor' section at https://investors.inmedpharma.com. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

  • Market Exclusive5 months ago

    Cannabis Stock News Daily Roundup December 5

    The global legal cannabis market is projected to hit $146.4 billion by end of 2025, according to research by Grand View Research. The legal cannabis industry is gaining traction worldwide due to high demand among consumers for recreational and medical products. Recreational cannabis spending is projected to hit $35 Billion mark, while medical cannabis spending […] The post Cannabis Stock News Daily Roundup December 5 appeared first on Market Exclusive.

  • InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program
    PR Newswire5 months ago

    InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program

    OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, is pleased to announce that it has signed a contribution agreement with the National Research Council Canada Industrial Research Assistance Program ("NRC IRAP") to receive funding of up to C$500,000 to support InMed's ongoing R&D efforts in cannabinoid biosynthesis. NRC IRAP provides advisory services and funding to Canadian businesses to promote accelerated growth and technology innovation.